FibroBiologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.49 million compared to USD 5.12 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.31 USD | +5.21% | -4.15% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 367M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.23% | 21.58B | |
-10.90% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023